Polycaprolactone-loaded bone mesenchymal stem cell-derived apoptotic bodies (PCL-BMSC-ABs) guided in vitro polarization of M0 to M2 macrophages (Mϕs). (IMAGE)
Caption
(A) Immunostaining of 0–100 μg/mL PCL-BMSC-ABs incubated for 4 h. Green: cytoplasm; blue: nucleus; red: ABs. (B) Immunostaining of 0–100 μg/mL PCL-ABs incubated for 6 h. Green: cytoplasm; blue: nucleus; red: ABs. (C) Relative fluorescence intensity of 0–100 μg/mL PCL-BMSC-ABs incubated for 4 h and 6 h n = 3; ∗∗P < 0.01. (D) RAW264.7 cell viability after incubation with PCL-ABs. (E) Western blot analysis of Mϕs reprogrammed with the M2 phenotype treated with 50 μg/mL PCL-ABs. (F) Relative grayscale values of western blot analysis of 50 μg/mL PCL-BMSC-ABs Mϕs reprogrammed with the M2 phenotype. n = 3; ∗∗P < 0.01, ∗P < 0.05. (G) Flow cytometry comparison of CD206-positive M1 Mϕs and Mϕs incubated with 50 μg/mL PCL-BMSC-ABs for different periods.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND